- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Aliso Viejo Today
By the People, for the People
Stifel Nicolaus Lowers Price Target for RxSight Stock
Analysts cite concerns about the medical technology company's future performance.
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Equity researchers at Stifel Nicolaus have decreased their price objective on shares of RxSight (NASDAQ:RXST) from $10.00 to $9.00 and maintained a "hold" rating on the stock. The brokerage firm cited uncertainty around the company's future outlook in a research report issued on Monday.
Why it matters
RxSight is a medical technology company focused on developing and commercializing advanced intraocular lens (IOL) systems for cataract surgery patients. The lowered price target from Stifel Nicolaus suggests analysts have growing concerns about the company's ability to execute on its growth plans and achieve profitability in the near term.
The details
In their research report, Stifel Nicolaus analysts noted that the reduced price target reflects their more cautious view on RxSight's prospects. The firm cited factors such as increased competition in the IOL market and potential challenges in driving adoption of RxSight's flagship Light Adjustable Lens product.
- Stifel Nicolaus issued the updated research report and price target on Monday, March 9, 2026.
The players
Stifel Nicolaus
A global wealth management and investment banking firm that provides securities brokerage, investment banking, trading, investment advisory, and related financial services.
RxSight
A medical technology company focused on developing and commercializing advanced intraocular lens (IOL) systems for cataract surgery patients.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
The lowered price target from Stifel Nicolaus reflects growing concerns about RxSight's ability to maintain its competitive edge and drive adoption of its innovative IOL technology in an increasingly crowded market. Investors will be closely watching the company's upcoming financial results and strategic initiatives to gauge its long-term prospects.
